Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Gottlieb

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
JAMA Health Forum|April 11, 2024
Bolstering FDA Pathways for Reducing Death and Disease from TobaccoScott Gottlieb, Mark B McClellan
The New England Journal of Medicine|January 24, 2019
The Next Phase of Human Gene-Therapy OversightFrancis S Collins, Scott Gottlieb
The New England Journal of Medicine|August 2, 2008
Pharmaceutical promotion and First Amendment rightsDaniel E Troy, Scott Gottlieb
JAMA|July 5, 2018
FDA Regulation of Mobile Medical AppsJeffrey Shuren, Bakul Patel, Scott Gottlieb
The New England Journal of Medicine|May 31, 2018
The FDA and the Next Wave of Drug Abuse - Proactive PharmacovigilanceDouglas C Throckmorton, Scott Gottlieb, Janet Woodcock
Oncology (Williston Park, N.Y.)|July 2, 2011
Oncology Care in 2021: the FDA, Medicare, and healthcare reformScott Gottlieb, Thomas A Gustafson, Daniel H Johnson
American Journal of Clinical Dermatology|February 26, 2004
The wrinkle severity rating scale: a validation studyDoris J Day, Curt M Littler, Richard W Swift, et al.
Health Affairs (Project Hope)|January 21, 2021
Health Costs And Financing: Challenges And Strategies For A New AdministrationWilliam H Shrank, Nancy-Ann DeParle, Scott Gottlieb, et al.
Dermatology and Therapy|January 7, 2026
Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-AnalysisScott Gottlieb, Aaron S Farberg, Neal Bhatia, et al.
The New England Journal of Medicine|December 3, 2025
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDARobert M Califf, Andrew C von Eschenbach, Michael A Friedman, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
JAMA Health Forum|April 11, 2024
Bolstering FDA Pathways for Reducing Death and Disease from TobaccoScott Gottlieb, Mark B McClellan
The New England Journal of Medicine|January 24, 2019
The Next Phase of Human Gene-Therapy OversightFrancis S Collins, Scott Gottlieb
The New England Journal of Medicine|August 2, 2008
Pharmaceutical promotion and First Amendment rightsDaniel E Troy, Scott Gottlieb
JAMA|July 5, 2018
FDA Regulation of Mobile Medical AppsJeffrey Shuren, Bakul Patel, Scott Gottlieb
The New England Journal of Medicine|May 31, 2018
The FDA and the Next Wave of Drug Abuse - Proactive PharmacovigilanceDouglas C Throckmorton, Scott Gottlieb, Janet Woodcock
Oncology (Williston Park, N.Y.)|July 2, 2011
Oncology Care in 2021: the FDA, Medicare, and healthcare reformScott Gottlieb, Thomas A Gustafson, Daniel H Johnson
American Journal of Clinical Dermatology|February 26, 2004
The wrinkle severity rating scale: a validation studyDoris J Day, Curt M Littler, Richard W Swift, et al.
Health Affairs (Project Hope)|January 21, 2021
Health Costs And Financing: Challenges And Strategies For A New AdministrationWilliam H Shrank, Nancy-Ann DeParle, Scott Gottlieb, et al.
Dermatology and Therapy|January 7, 2026
Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-AnalysisScott Gottlieb, Aaron S Farberg, Neal Bhatia, et al.
The New England Journal of Medicine|December 3, 2025
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDARobert M Califf, Andrew C von Eschenbach, Michael A Friedman, et al.
Pageof 9